Phenylephrine

• Description:

  (R) - (-) -Phenylephrine is a selective α1-adrenoceptor agonist primarily used as a decongestant.

• Product Name Alternative:

  (R) - (-) -Phenylephrine; L-Phenylephrine

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H318, H335

• Target:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cardiovascular Disease; Endocrinology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/_R_-_-_-Phenylephrine.html

• Purity:

  99.98

• Solubility:

  DMSO : 50 mg/mL (ultrasonic) |H2O : 5 mg/mL (ultrasonic)

• Smiles:

  O[C@H](C1=CC(O)=CC=C1)CNC

• Molecular Formula:

  C9H13NO2

• Molecular Weight:

  167.21

• Precautions:

  H302, H315, H318, H335

• References & Citations:

  [1]Ford AP, et al. Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications foralpha1-adrenoceptor classification. Br J Pharmacol. 1997 Jul;121 (6) :1127-35.|[2]Minneman KP, et al. Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46 (5) :929-36.|[3]Wang J, et al. Phenylephrine promotes cardiac fibroblast proliferation through calcineurin-NFAT pathway. Front Biosci (Landmark Ed) . 2016 Jan 1;21:502-13.|[4]Lazou A, et al. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by the G-protein-coupled receptor agonist phenylephrine in the perfused rat heart. Biochem J. 1998 Jun 1;332 (Pt 2) :459-65.|[5]Li NJ, et al. Effect of phenylephrine on alveolar fluid clearance in ventilator-induced lung injury. Chin Med Sci J. 2013 Mar;28 (1) :1-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  α adrenergic receptor

• Citation 01:

  Biochem Biophys Res Commun. 2024 Nov 26:735:150844.|Biochem Pharmacol. 2025 Aug 8;242 (Pt 1) :117218.|Biochem Pharmacol. 2025 Oct:240:117107.|Biochim Biophys Acta Mol Basis Dis. 2024 Aug 30:167488.|Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870 (1) :166859.|BMC Cardiovasc Disord. 2025 Jan 6;25 (1) :7.|BMC Pulm Med. 2021 Jun 5;21 (1) :189.|Cell Signal. 2026 Feb:138:112275.|Clin Exp Pharmacol Physiol. 2025 Nov;52 (11) :e70081.|Eur J Pharmacol. 2025 Feb 1:177346.|FASEB J. 2025 May 31;39 (10) :e70670.|Free Radic Biol Med. 2025 Jun 7:237:300-311.|Front Med. 2024 Jun;18 (3) :484-498.|Int Endod J. 2025 Jul 14.|J Adv Res. 2025 Oct 29:S2090-1232 (25) 00848-3.|J Cardiovasc Pharmacol. 2022 Sep 1;80 (3) :430-441.|J Endod. 2023 Dec;49 (12) :1641-1651.e6.|J Ethnopharmacol. 2024 Aug 22:118707.|Mol Med Rep. 2021 Sep;24 (3) :636.|Nat Commun. 2024 Jul 16;15 (1) :5985.|Phytother Res. 2025 May 26.|Sci Rep. 2023 Oct 2;13 (1) :16550.|Sci Rep. 2025 Apr 11;15 (1) :12511.|Trends Biotechnol. 2025 Apr;43 (4) :918-945.|bioRxiv. 2025 Jul 30.|bioRxiv. 2025 Jun 27:2025.06.24.660441.|Elife. 2024 May 29.|Free Radic Biol Med. 2024 Feb 20:212:477-492.|Front Cardiovasc Med. 2021 Jun 16:8:679240.|J Cell Mol Med. 2025 Mar;29 (5) :e70488.|J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15:1092:220-227.|Mater Des. 2025 Aug.

• CAS Number:

  59-42-7